Article Text

other Versions

PDF
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study.
  1. Geertje M Bartelds (m.bartelds{at}janvanbreemen.nl)
  1. Jan van Breemen Institute, Netherlands
    1. Carla A Wijbrandts (c.a.wijbrandts{at}amc.uva.nl)
    1. AMC/University Medical Center, Netherlands
      1. Michael T Nurmohamed (m.nurmohamed{at}janvanbreemen.nl)
      1. VU University medical center, Netherlands
        1. Steven O Stapel (s.stapel{at}sanquin.nl)
        1. Sanquin, Netherlands
          1. Willem F Lems (wf.lems{at}vumc.nl)
          1. VU University Medical Center, Netherlands
            1. Lucien Aarden (l.aarden{at}sanquin.nl)
            1. Sanquin, Netherlands
              1. Ben A C Dijkmans (bac.dijkmans{at}vumc.nl)
              1. VU University Medical Center, Netherlands
                1. Paul Peter Tak (p.p.tak{at}amc.uva.nl)
                1. AMC Amsterdam, Netherlands
                  1. Gerrit Jan Wolbink (g.wolbink{at}janvanbreemen.nl)
                  1. Jan van Breemen Institute, Netherlands

                    Abstract

                    Objective To investigate how antibodies against anti-TNF agents influence response after switching from infliximab to adalimumab in rheumatoid arthritis (RA).

                    Methods: This cohort study consisted of 235 RA patients, all treated with adalimumab. At baseline fifty-two patients (22%) were previously treated with infliximab ("switchers"), and 183(78%) were anti-TNF naive. Disease activity (using the DAS28score) and presence of antibodies against infliximab and adalimumab was assessed. Clinical response to adalimumab was compared between switchers and anti-TNF naive patients and their anti-infliximab and anti-adalimumab antibody status.

                    Results After 28 weeks of adalimumab therapy the decrease in DAS28 (ΔDAS28) for the 235 patients was 1.6±1.5 (mean±SD). Anti-adalimumab antibodies were detected in 46 patients (20%). ΔDAS28 was 1.8±1.4 in patients without anti-adalimumab and 0.6±1.3 in patients with anti-adalimumab (P<0.0001). Thirty-three out of the 52 switchers (63%) had anti-infliximab antibodies. Patients with anti-infliximab more often developed anti-adalimumab than anti-TNF naive patients, (11(33%) versus 32(18%);(P=0.039)). ΔDAS28 was greater for anti-TNF naive patients (1.7±1.5) compared to switchers without anti-infliximab antibodies (ΔDAS28=0.9±1.4) (P=0.009). ΔDAS28 for switchers with anti-infliximab was 1.2±1.3 and did not differ significantly from anti-TNF naive patients (P=0.262).

                    Conclusion Switchers with anti-infliximab antibodies more often develop antibodies against adalimumab than anti-TNF naive patients. Response to adalimumab was limited in switchers without anti-infliximab antibodies, which raises the question whether a second anti-TNF therapy should be offered to RA-patients who fail on initial treatment with anti-TNF, in the absence of anti-biological antibodies.

                    Statistics from Altmetric.com

                    Request permissions

                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.